NCT03068312View on ClinicalTrials.gov

A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 18, 2017

Primary Completion Date

December 18, 2018

Study Completion Date

December 18, 2018

Conditions

Cystic Fibrosis

Interventions

DRUG

Ivacaftor

IVA 150 mg tablet.

DRUG

Placebo

Placebo matched to IVA tablet.

Trial Locations (1)

Unknown

Hadassah Medical Organization, Jerusalem

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT03068312 - A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation | Biotech Hunter | Biotech Hunter